Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by JING WANG and JOHN VICTOR HEYMACH.
JING WANG
Connection Strength
1.417
JOHN VICTOR HEYMACH
  1. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014 Jul 31; 511(7511):543-50.
    View in: PubMed
    Score: 0.508
  2. drexplorer: A tool to explore dose-response relationships and drug-drug interactions. Bioinformatics. 2015 May 15; 31(10):1692-4.
    View in: PubMed
    Score: 0.132
  3. Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics. 2014 Dec 08; 15:1079.
    View in: PubMed
    Score: 0.131
  4. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90.
    View in: PubMed
    Score: 0.113
  5. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012 Sep; 2(9):798-811.
    View in: PubMed
    Score: 0.112
  6. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol. 2010 Dec; 5(12):1894-904.
    View in: PubMed
    Score: 0.099
  7. Blasted cell line names. Cancer Inform. 2010 Oct 14; 9:251-5.
    View in: PubMed
    Score: 0.098
  8. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res. 2014 Jul 15; 20(14):3849-61.
    View in: PubMed
    Score: 0.031
  9. An integrin ?3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014 May; 16(5):457-68.
    View in: PubMed
    Score: 0.031
  10. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75.
    View in: PubMed
    Score: 0.030
  11. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6322-8.
    View in: PubMed
    Score: 0.030
  12. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One. 2012; 7(2):e31087.
    View in: PubMed
    Score: 0.027
  13. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.
    View in: PubMed
    Score: 0.027
  14. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011 Aug 15; 71(16):5512-21.
    View in: PubMed
    Score: 0.026
  15. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res. 2009 Nov 15; 15(22):6852-61.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.